LLY vs SNY
Eli Lilly and Company vs Sanofi — AI-powered side-by-side comparison
LLY
Eli Lilly and Company
68
Buy
VS
| Metric | LLY | SNY |
|---|
| AI Score |
68
|
68
|
| Price |
$1,180.33
|
$43.70
|
| P/E Ratio |
39.54×
|
23.09×
|
| ROE |
77.8%
|
10.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
84.0%
|
72.8%
|
| Debt / Equity |
1.62×
|
0.34×
|
| Dividend Yield |
0.6%
|
5.5%
|
| RSI (14) |
57.1
|
56.9
|
| Beta |
0.506
|
0.278
|
| Expected Upside |
+5.8%
|
+3.5%
|
AI Committee View
Current Innellis committee reasoning for LLY versus SNY.
The committee scores are tied.
LLY and SNY both score 68/100.
LLY Committee View
75% agreement
4 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
SNY Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.28) -- balance sheet can absorb a shock. The main limiting factor is eps declining -37.4% yoy despite any revenue growth. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- Dividend yield of 5.4% pays you to wait — Value
- Revenue growing 39.5% YoY -- genuine top-line momentum — Growth
Bear Case
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth